SAN ANTONIO--(BUSINESS WIRE)--AdnaGen AG, a subsidiary of OncoVista Innovative Therapies, Inc. (OTCBB: OVIT), a high-growth global biotech company developing proprietary, leading-edge early detection and drug technologies to enable safe, targeted personal cancer treatments, today announced that it has entered into an option agreement to license specific antibodies to KellBenx Inc., a New York-based private biotech firm.
